CHRONIC URTICARIA: CLINICAL MANAGEMENT AND PHARMACOLOGICAL APPROACHES
Keywords:
Chronic Urticaria, Antihistamines, Omalizumab, BTK Inhibitors, Clinical Management, AngioedemaAbstract
Chronic urticaria (CU) is a heterogeneous dermatological condition characterized by persistent hives and angioedema lasting more than six weeks, with a significant impact on quality of life. This narrative review analyzes current guidelines and pharmacological innovations for the management of the disease. First-line treatment is based on second-generation H1 antihistamines, whose dose can be escalated up to four times to control symptoms. For refractory cases, the monoclonal antibody omalizumab has established itself as an effective and safe adjuvant therapy. The review also highlights promising emerging therapies, such as Bruton's tyrosine kinase (BTK) inhibitors, and discusses management in special populations, such as pregnant women. It concludes that a stepped and personalized approach is essential for disease control.
